MedTrace Logo

Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital

NCT05549232 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2025-07-23

Study results available
· View outcomes & findings →

Summary

The overall objective of this study is to collect preliminary safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with burns and patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021.

Conditions

  • Hematologic Neoplasms
  • Burns

Interventions

DEVICE

Hypoxic Red Blood Cells

Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced

Sponsors & Collaborators

  • Hemanext

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-24
Primary Completion
2024-05-16
Completion
2024-05-16
FDA Device
Yes

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05549232 on ClinicalTrials.gov